Edap TMSFOCL +1.91%53 ROE % is -246.20% as of Mar. 2026. GuruFocus rates FOCL with a GF Score™ of 53/100 and a GF Value™ of $4.52 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 115 Medical Distribution companies, Edap TMS ranks worse than 98.26% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Edap TMS's annualized net income for the quarter that ended in Mar. 2026 was $-36.3 Mil. Edap TMS's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was $14.8 Mil. Therefore, Edap TMS's annualized ROE % for the quarter that ended in Mar. 2026 was -246.20%.
The historical rank and industry rank for Edap TMS's ROE % or its related term are showing as below:
FOCL'
s ROE % Range Over the Past 10 Years
Min: -173.28 Med: -3.82 Max: 19.48
Current: -173.28
During the past 13 years, Edap TMS's highest ROE % was 19.48%. The lowest was -173.28%. And the median was -3.82%.
FOCL's ROE % is ranked worse than 98.26% of 115
companies
in the Medical Distribution industry
Industry Median: 7.1
vs FOCL: -173.28
Edap TMS (NAS:FOCL) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Edap TMS ROE % Related Terms
Edap TMS ROE % Historical Data
* Premium members only.
The historical data trend for Edap TMS's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Edap TMS's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Edap TMS ROE % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Edap TMS's ROE % distribution charts can be found below:
* The bar in red indicates where Edap TMS's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Edap TMS (FOCL) has a ROE % of -246.20% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Edap TMS and its competitors. According to the industry distribution chart, Edap TMS ranks #113 out of 115 companies in the Medical Distribution industry, placing it in the top 98.3%.
Is Edap TMS's ROE % too high?
Edap TMS's current ROE % is -246.20%. Based on the distribution chart, Edap TMS ranks #113 out of 115 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Edap TMS has a GF Score™ of 53/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Edap TMS's ROE % compare to ACH and YI?
According to the Medical Distribution industry distribution chart, Edap TMS ranks #113 out of 115 companies for ROE %. This places Edap TMS in the lower half of its industry. The industry median ROE % is 7.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Distribution company?
The median ROE % among Medical Distribution companies is 7.10, based on 115 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Edap TMS and its competitors. For the Medical Distribution industry, the median ROE % is 7.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Edap TMS's current ROE % is -246.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edap TMS stock overvalued right now?
Based on GuruFocus' analysis, Edap TMS (FOCL) is currently considered Modestly Overvalued. The stock's GF Value™ is $4.52, compared to a current price of $5.08 — trading 12.3% above its estimated fair value. The current ROE % is -246.20%. Edap TMS's overall GF Score™ is 53/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Edap TMS (FOCL), the current ROE % is -246.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Edap TMS (FOCL) Overvalued in 2026?
Based on GuruFocus' analysis, Edap TMS stock appears to be overvalued.
The current stock price of $5.08 is trading 12.3% above its estimated GF Value™ of $4.52.
GuruFocus considers Edap TMS to be Modestly Overvalued.
Key valuation signals for FOCL:
ROE %: -246.20%
GF Value™: $4.52 vs. price of $5.08 (12.3% above fair value)
No single metric tells the full story. See the FOCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Edap TMS SA, formerly known as FocalTherics, operates in the Robotic Focal Therapy industry. It develops, manufactures, and markets minimally invasive medical devices across various countries to treat various conditions using proprietary focused ultrasound technology. The company's flagship platform, Focal One Robotic HIFU, combines imaging, real-time treatment planning, robotic precision, and high intensity focused ultrasound (HIFU) technology. It is focused on expanding the clinical adoption of its patented focused ultrasound-based robotic therapy platforms through continued innovation, clinical evidence generation, physician education, and various market development initiatives.
53GF Score
Get the complete analysis for FOCL
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FOCL has been successfully added to your 
